Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[CD44 expression: a new prognostic factor in neuroblastoma].

V Combaret1, C Lasset, R Bouvier

  • 1Laboratoire de biologie cellulaire, centre Léon-Bérard, Lyon, France.

Bulletin Du Cancer
|January 1, 1995
PubMed
Summary

CD44 expression is a strong predictor of favorable outcomes in neuroblastoma (NB). Lower CD44 levels indicate aggressive tumors, while higher levels correlate with better survival, suggesting CD44 as a key prognostic marker.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.

Oral oncology·2024
Same author

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

ESMO open·2021
Same author

Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2020
Same author

The European Society of Paediatric Oncology Ependymoma-II program Core-Plus model: Development and initial implementation of a cognitive test protocol for an international brain tumour trial.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2019
Same author

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • CD44 gene products are recognized as potential indicators of tumor aggressiveness across various cancer models.
  • This observation prompted an investigation into the role of CD44 in clinical neuroblastoma (NB) specimens.

Purpose of the Study:

  • To evaluate the expression of CD44 in neuroblastoma.
  • To determine the correlation between CD44 expression levels and tumor aggressiveness, patient survival, and other prognostic factors.

Main Methods:

  • Immunostaining was performed on 52 neuroblastoma specimens using a monoclonal antibody targeting common CD44 isoforms.
  • Tumors were classified according to international criteria, and CD44 immunoreactivity was assessed.
  • Prognostic value was analyzed through univariate and multivariate analyses, comparing CD44 expression with tumor stage, age, histology, and N-myc amplification.

Related Experiment Videos

Main Results:

  • CD44 immunoreactivity was detected in 71% of neuroblastoma tumors.
  • CD44 was expressed in 100% of favorable NB stages (1, 2, 4S) but only 50% of advanced stages (3, 4) (p = 0.0001).
  • CD44-positive tumors showed significantly longer event-free survival (p < 10(-5)) and progression-free survival, even in high-risk groups (p < 0.01).
  • CD44 expression and absence of N-myc amplification were the strongest predictors of favorable outcome.
  • Multivariate analysis identified CD44 expression and tumor stage as independent prognostic factors for patient survival.

Conclusions:

  • Neuroblastoma aggressiveness correlates with reduced CD44 expression, not overexpression.
  • CD44 serves as a significant independent prognostic marker for neuroblastoma.
  • The study recommends incorporating CD44 into the initial staging of neuroblastoma for improved patient management.